Northeast Pharmaceutical Group (SHE:000597) received approval to market raw drug material Efavirenz from the Chinese drug administration, according to a Shenzhen Stock Exchange disclosure on Saturday.

The approval is valid until Feb. 11, 2030.

Efavirenzis a key drug ingredient for the treatment of human immunodeficiency virus infection and a selective non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), the pharmaceutical company said.